This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
GSK's Myelofibrosis Candidate MAA Gets Accepted in Europe
by Zacks Equity Research
GSK's new drug application (NDA) for momelotinib is under standard FDA review, with a decision expected on Jun 16, 2023.
The Zacks Analyst Blog Highlights Caterpillar, Merck, UnitedHealth Group and Walmart
by Zacks Equity Research
Caterpillar, Merck, UnitedHealth Group and Walmart are included in this Analyst Blog.
Should Investors Consider These 3 Low-Beta Stocks?
by Derek Lewis
During times of heightened volatility, adding low-beta stocks can help blend in an extra layer of portfolio defense.
Top 4 Blue-Chip Stocks to Enhance Your Portfolio in December
by Nalak Das
We have narrowed our search to four Dow stocks. These are: CAT, WMT, MRK, UNH.
3 Reasons Growth Investors Will Love Merck (MRK)
by Zacks Equity Research
Merck (MRK) could produce exceptional returns because of its solid growth attributes.
Why Is Lilly (LLY) Up 4.5% Since Last Earnings Report?
by Zacks Equity Research
Lilly (LLY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Merck (MRK) Is Considered a Good Investment by Brokers: Is That True?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Merck (MRK). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
3 Stocks to Watch That Recently Announced Dividend Hikes
by Ritujay Ghosh
Merck & Co., Inc. (MRK), McCormick & Company, Incorporated (MKC) and Tsakos Energy Navigation Limited (TNP) recently hiked dividends.
AstraZeneca (AZN) Boosts Cell Therapies With Neogene Deal
by Zacks Equity Research
The acquisition of Neogene is set to give AstraZeneca (AZN) access to the latter's next-generation T-cell receptor therapies.
Is Most-Watched Stock Merck & Co., Inc. (MRK) Worth Betting on Now?
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.
Should Invesco Dow Jones Industrial Average Dividend ETF (DJD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DJD
Factors That Make Elevance Health (ELV) a Lucrative Bet Now
by Zacks Equity Research
Elevance Health (ELV) continues to benefit from sustained top-line growth, higher membership in Government business and a sturdy financial position.
Should Value Investors Buy Innoviva (INVA) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Merck & Co., Inc. (MRK) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Merck (MRK) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Clovis (CLVS) Stock Down 50% in the Past 6 Months: Here's Why
by Zacks Equity Research
Clovis Oncology (CLVS) tanks in the past six months following the possibility of a bankruptcy filing in the near term.
Pharma Stock Roundup: MRK to Buy IMGO, ABBV's Skyrizi Gets EU Nod for New Indication
by Kinjel Shah
Merck (MRK) offers to buy Imago Biosciences (IMGO). The European Commission approves AbbVie's (ABBV) immunology medicine, Skyrizi for Crohn's disease.
Novartis (NVS) Set to Advance Malaria Drug Into Phase III
by Zacks Equity Research
Novartis (NVS) plans to advance ganaplacide/lumefantrine into a phase III study for the treatment of patients with acute uncomplicated malaria due to Plasmodium falciparum.
Mirati's (MRTX) Stock Rallies 11% on Buyout Speculations
by Zacks Equity Research
Mirati Therapeutics' (MRTX) new drug application (NDA), seeking approval for adagrasib, its KRAS inhibitor drug, for previously-treated KRASG12C-mutated NSCLC is under review with the FDA with a decision expected by Dec 14.
AbbVie's (ABBV) Skyrizi Gets EU Nod for Crohn's Disease
by Zacks Equity Research
AbbVie's (ABBV) Skyrizi becomes the first specific IL-23 inhibitor to get approval for Crohn's disease in the European Union.
Merck (MRK) Keytruda Advanced Gastric Cancer Study Meets Goal
by Zacks Equity Research
Top-line data from a late-stage study shows that Merck's (MRK) Keytruda combined with chemotherapy improved overall survival in patients with advanced gastric cancer.
GSK to Withdraw Blenrep From U.S. Market on FDA Request
by Zacks Equity Research
GSK, at the request of the FDA, is set to withdraw the U.S. marketing authorization for Blenrep. The FDA's request comes after the failure of a phase III confirmatory study, DREAMM-3.
The Zacks Analyst Blog Highlights Archer-Daniels-Midland, McKesson, Marathon Petroleum, Exxon Mobil and Merck & Co
by Zacks Equity Research
Archer-Daniels-Midland, McKesson, Marathon Petroleum, Exxon Mobil and Merck & Co are part of the Zacks top Analyst Blog.
Encompass Health (EHC) Proposes 50-Bed Hospital in Florida
by Zacks Equity Research
Encompass Health (EHC) intends to build a 50-bed inpatient rehabilitation hospital in the Daytona Beach area to further amplify its presence in Florida.
Imago (IMGO) Shares Surge 104% on Buyout Offer From Merck
by Zacks Equity Research
Imago BioSciences (IMGO) to be acquired by pharma-giant Merck (MRK) for $1.35 billion. The transaction is likely to close by first-quarter 2023.
Buy These 5 Corporate Giants Flying High in Disappointing 2022
by Nalak Das
We have narrowed our search to five U.S. corporate behemoths that have popped year to date. These are: ADM, MPC, XOM, MRK and MCK.